Evidence map›Paper›PMID 25000457›Full record

ArticleBone marrow transplantation2014

Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT.

S Fuji, J Kanda, S Kato, K Ikegame, S Morishima, T Miyamoto, M Hidaka, K Kubo, K Miyamura, K Ohashi and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 1 country.

S FujiHematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
J KandaDivision of Hematology, Saitama Medical Center, Saitama, Japan.
S KatoDepartment of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Kanagawa, Japan.
K IkegameDivision of Hematology, Department of Internal Medicine, Hyogo Medical College, Hyogo, Japan.
S MorishimaDepartment of Hematology, Fujita Health University School of Medicine, Nagoya, Japan.
T MiyamotoDepartment of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan.
M HidakaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
K KuboDepartment of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan.
K MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
K OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan.
H KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Y MaesakoDepartment of Hematology, Tenri Hospital, Nara, Japan.
S AdachiHuman Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
T IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Y AtsutaDepartment of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Y KandaDivision of Hematology, Saitama Medical Center, Saitama, Japan.
HLA Working Group of Japan Society for Hematopoietic Cell Transplantation
Aomori Prefectural Central Hospital · JPFujita Health University · JPHiroshima University · JPHyogo Medical University · JPKumamoto Medical Center · JPKyoto University · JPKyushu University Hospital · JPNagano Red Cross Hospital · JPNagoya University · JPSaitama Medical University · JPSocial Insurance Saitama Chuo Hospital · JPTenri Hospital · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In unrelated hematopoietic SCT (HSCT), HLA allele mismatch has been shown to have a significant role. To clarify the importance of HLA allele mismatch in the GVH direction in related HSCT, we retrospectively evaluated 2377 patients who received stem cells from an HLA serologically matched related donor in the GVH direction using the database of the Japan Society for Hematopoietic Cell Transplantation. The cumulative incidences of grade II-IV and grade III-IV acute GVHD in patients with an HLA allele-mismatched donor (n=133, 5.6%) were significantly higher than those in patients with an HLA allele-matched donor. Multivariate analyses showed that the presence of HLA allele mismatch was associated with increased risks of grade II-IV and grade III-IV acute GVHD. In particular, HLA-B mismatch and multiple allele mismatches were associated with an increased risk of acute GVHD. The presence of HLA allele mismatch was associated with an inferior OS owing to an increased risk of non-relapse mortality (NRM). In conclusion, the presence of HLA allele mismatch in the GVH direction in related HSCT was associated with increased risks of GVHD and NRM, which led to an inferior OS. HLA allele typing is recommended in related HSCT.

Indexed as

AdolescentAdultAgedAllelesChildChild, PreschoolCohort StudiesFemaleHematopoietic Stem Cell TransplantationHistocompatibilityHLA AntigensHumansInfantMaleMiddle AgedTransplantation ConditioningHLA Antigens

Identifiers

PMID25000457
OpenAlexW2026608692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.